Resources
Here you can find publications and other resources related to the DOASENSE products.
Please note that our products are for health care professional use only!
Recent Publications
- Harenberg J, Loesel F, Douxfils J, Elalamy I, Bauersachs R, Beyer-Westendorf J, Crowther M, Verhamme P, Hetjens S, Weiss C:Comparison of visual versus reader results of the point of care test of direct oral anticoagulants from urine samplesISTH 2020, Poster PB0590 [view poster]
- Harenberg J, Bauersachs R, Beyer-Westendorf J, Crowther M, Douxfils J, Elalamy I, Hetjens S, Verhamme P, Weiss C:Inter-centre and inter-observer agreement of determination of DOACs in urine samples of patients by means of DOAC Dipstick testISTH 2020, Poster PB0525 [view poster]
- Harenberg J, Beyer-Westendorf J, Crowther M, Douxfils J, Elalamy I, Verhamme P, Bauersachs R, Hetjens S, Weiss C:
Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine — A Multicenter Trial
Thromb Haemost 2020; 120(01): 132-140
[Free open access download HERE]
- Favaloro EJ, Lippi G:
The Pointy End of Point-of-Care Testing for Direct Oral Anticoagulants
Thromb Haemost 2020;120:11–13. [download editorial]
- Harenberg J, Schreiner H, Hetjens S, Weiss C:
Detecting Anti-IIa and Anti-Xa Direct Oral Anticoagulant (DOAC) Agents in Urine using a DOAC Dipstick.
Semin Thromb Hemost 2019; 45: 275–284
[Free open access download HERE]
- Robert C. Gosselin, Dorothy M. Adcock, Jonathan Douxfils:
An update on laboratory assessment for direct oral anticoagulants (DOACs)
Int J Lab Hematol. 2019;41(Suppl. 1):33–39 [article]
- Brigitte Söllner:
DOAC Dipstick: Einfacher Nachweis von direkten oralen Antikoagulanzien aus dem Urin
Perfusion 2/2019: 54-56 (in German) [download article]
- Robert C. Gosselin, Dorothy M. Adcock, Shannon M. Bates, Jonathan Douxfils, Emmanuel J. Favaloro, Isabelle Gouin-Thibault, Cecilia Guillermo, Yohko Kawai, Edelgard Lindhoff-Last, Steve Kitchen:
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
Thromb Haemost 2018; 118(3): 437-450 [ICSH Guidelines] - J. Harenberg, S. Hetjens, R. Schreiner, R. Krämer, C. Weiss:
DOAC Dipstick for determination of absence or presence of direct oral anticoagulants and creatinine in urine
Res Pract Thromb Haemost 2018; 2(Suppl. 1): PB242 [Poster]
- J. Harenberg, U. Warttinger, S. Hetjens, R. Schreiner, C. Giese, H.-J. Roth, R. Krämer, C. Weiss:
Reliability and validity of point-of-care tests taken from urine samples of patients on therapy with Apixaban, Rivaroxaban and Dabigatran
Res Pract Thromb Haemost 2017; 1(Suppl1): PB454 [Poster]
- Harenberg J, Ahrens I, Bauersachs R, Haas S, Koscielny J, Kraemer R, Lindhoff-Last E, Prochaska J, Schellong S, Spannagl M, Wild P, Beyer-Westendorf J:
A qualitative point of care test to assess anticoagulant activity in urine samples of patients treated with non-vitamin K antagonist oral anticoagulants - a german consensus.
J Thromb Haemost 2015; 13(Suppl 2): 636-637 (PO356-Tue)
- Harenberg J, Du S, Wehling M, Zolfaghari S, Weiss C, Krämer R, Walenga J:
Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
Clin Chem Lab Med. 2016 Feb 1; 54(2): 275-83
- Favaloro EJ, Lippi G:
Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors.
Semin Thromb Hemost. 2015 Mar; 41(2): 208-27
- Harenberg J, Du S, Krämer R, Weiss C, Krämer R, Wehling M:
Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants.
Semin Thromb Hemost. 2015 Mar; 41(2): 228-36
- Harenberg J, Du S, Krämer R, Weiss C:
Correctness of the identification by patients of colour of urine samples obtained a point of care test for dabigatran and rivaroxaban
J Thromb Haemost 2013, 11 (Suppl 1) PB 4.45-05 [read HERE]
- Harenberg J, Krämer S, Du S, Weiss C, Krämer R:
Concept of a point of care test to detect new oral anticoagulants in urine samples.
Thromb J. 2013 Aug 1; 11(1):15
Related Information
“When every minute counts” is best illustrated by this article, evidencing the importance of rapid treatment and therefore DOAC testing for ischemic patients.
“Among patients aged 65 years or older with acute ischemic stroke, who were treated with tissue plasminogen activator, shorter door to needle time were associated with lower all-cause mortality and lower all-cause readmission at 1 year. The findings support efforts to shorten time to thrombolytic therapy":
“Among patients aged 65 years or older with acute ischemic stroke, who were treated with tissue plasminogen activator, shorter door to needle time were associated with lower all-cause mortality and lower all-cause readmission at 1 year. The findings support efforts to shorten time to thrombolytic therapy":
- Man S, Xian Y, Holmes DN, Matsouaka RA, Saver JL, Smith EE, Bhatt DL, Schwamm LH, Fonarow GC:
Association Between Thrombolytic Door-to-Needle Time and 1-YearMortality and Readmission in Patients With Acute Ischemic Stroke
JAMA. 2020;323(21):2170-2184. DOI: 10.1001/jama.2020.5697 [read HERE]
- Drouet L, Harenberg J, Torri G:
The Multiple Faces of Heparin: Opportunities inCOVID-19 Infection and Beyond
Thromb Haemost 2020;120:1347–1350. DOI: 10.1055/s-0040-1716543 [download HERE]
- Harenberg J, Bauersachs R, Ageno W:
Does Chronic Treatment with Oral Anticoagulants Ameliorate the Clinical Course of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Coronavirus Disease 2019 (COVID-19)?Semin Thromb Hemost. DOI: 10.1055/s-0040-1715091 [download HERE]
Videos
Video material related to the DOASENSE product suite:
(Please also visit our online training website for further videos)
(Please also visit our online training website for further videos)
DOASENSE Technology Animation
Listen to what opinion leaders think about DOASENSE's scientific education activities (symposia, etc.):
NOTE: DOASENSE(TM) products may not be available or approved in your country.